GLP-1 medications compared for Australian patients cost, efficacy + access (2026)

The Health Desk · Editorial team, aged care + dental + plastic surgery + dermatology + weight-loss + psychology · Updated 14 May 2026 · How we rank · Editorial standards

Six GLP-1 (and GLP-1-adjacent) medications are commercially available in Australia in 2026. Only one has a PBS pathway. The "best" depends on your situation. This is the honest ranking based on trial efficacy, real-world cost, side effects, and access.

Key takeaways

  • PBS Ozempic for T2D is the cheapest option by a factor of 14 vs any private alternative.
  • For weight loss alone: Wegovy is the on-label, evidence-supported choice.
  • Mounjaro produces the most weight loss but costs the most. No PBS pathway.
  • Saxenda (daily injection) is largely superseded but still has niche uses.
  • Rybelsus (oral semaglutide) avoids injections but is rarely used for weight loss.

The headline ranking table

Rank Drug Best for Cost/month
#1 cheapestOzempic on PBST2D patients meeting Authority criteria$31.60
#1 efficacyMounjaroMaximum weight loss, cost not primary concern$450-$580
#1 on-label WLWegovyWeight loss without T2D, on-label option$420-$530
#1 cheapest WLOzempic off-labelCost-conscious private weight loss$380-$450
NicheSaxendaDaily injection preference, weekly intolerance$340-$420
NicheRybelsusNeedle-phobic T2D patientsPBS varies

#1 Mounjaro (tirzepatide), best for maximum weight loss

Eli Lilly's dual GIP/GLP-1 agonist. The newest entrant and the TGA-approved in trials. SURMOUNT-1 showed roughly 20% body weight loss at the 15mg dose over 72 weeks. Approved for type 2 diabetes; widely used off-label for weight management.

Cost: $450-$580/month at retail pharmacy. $400-$550 via telehealth bundle.

PBS: Not listed. Eli Lilly submissions are with the PBAC; outcomes pending.

Dose: Escalates 2.5mg → 5 → 7.5 → 10 → 12.5 → 15mg over 5-6 months.

Best for: Patients who have responded inadequately to maximum Ozempic dose, or those prioritising efficacy with cost as secondary. Detailed Ozempic vs Mounjaro comparison.

#2 Wegovy (semaglutide 2.4mg), best on-label weight loss option

Novo Nordisk's high-dose semaglutide product, TGA-approved specifically for chronic weight management. Same molecule as Ozempic but dosed higher. STEP trials show roughly 15% body weight loss at 2.4mg over 68 weeks.

Cost: $420-$530/month retail. $290-$450 via telehealth bundle.

PBS: Not listed.

Dose: 0.25mg → 0.5 → 1.0 → 1.7 → 2.4mg over 16-20 weeks.

Best for: Patients without T2D pursuing weight loss who want the on-label, evidence-supported option. Wegovy PBS coverage guide.

#3 Ozempic (semaglutide 0.25-1.0mg), best for T2D + cheapest off-label option

The original. Novo Nordisk's lower-dose semaglutide product, TGA-approved for type 2 diabetes. PBS-subsidised under Authority Streamlined for eligible T2D patients. Widely used off-label for weight loss.

Cost: $31.60 PBS (general T2D), $7.70 PBS (concession), $380-$450 private retail, $290-$420 via telehealth bundle.

PBS: Yes, Authority Streamlined for T2D meeting HbA1c criteria.

Dose: 0.25mg → 0.5 → 1.0mg over 8-12 weeks.

Best for: T2D patients (via PBS). Also viable off-label for weight loss patients prioritising cost. Ozempic PBS coverage guide.

#4 Saxenda (liraglutide 3mg), niche, daily injection

Novo Nordisk's daily liraglutide product, TGA-approved for chronic weight management. Now largely superseded by weekly options but still has a small role.

Cost: $340-$420/month private. No PBS for weight loss.

Dose: Daily injection (vs weekly for others). Escalates daily over 5 weeks.

Best for: Patients with severe injection anxiety who prefer smaller daily injections to larger weekly ones, or patients with specific gastroparesis where liraglutide's shorter half-life is preferred. Saxenda cost guide.

#5 Rybelsus (oral semaglutide), needle-free for T2D

Daily oral tablet form of semaglutide. TGA-approved for type 2 diabetes. PBS access varies by criteria. Rarely used for weight loss because available oral doses are lower-equivalent than injectable Ozempic.

Cost: PBS varies; private around $300-$400/month.

Dose: 3mg → 7mg → 14mg daily tablets.

Best for: Severely needle-phobic T2D patients who can comply with strict pre-dose fasting requirements (must be taken on empty stomach, no food/drink for 30 minutes after).

#6 Trulicity (dulaglutide), alternative weekly GLP-1 for T2D

Eli Lilly's once-weekly GLP-1 agonist, TGA-approved and PBS-subsidised for type 2 diabetes under specific Authority criteria. Less commonly discussed than Ozempic but a legitimate alternative for T2D patients.

Cost: $31.60 PBS (general T2D); private equivalent to Ozempic.

Best for: T2D patients where Ozempic supply is short or who prefer Lilly's auto-injector device.

Decision tree: which should you take?

  • Have T2D + HbA1c above threshold: PBS Ozempic. Period.
  • Weight loss only, cost-sensitive: Off-label Ozempic via telehealth bundle.
  • Weight loss only, want on-label option: Wegovy via telehealth bundle.
  • Weight loss only, maximum efficacy: Mounjaro via telehealth bundle.
  • Needle phobia + T2D: Rybelsus (oral semaglutide).
  • Daily injection preference: Saxenda.
  • Ozempic shortage: Trulicity (T2D) or Wegovy/Mounjaro (weight loss).

Compare your real out-of-pocket cost across options in our GLP-1 switch cost calculator.

Related coverage

Common questions

GLP-1 medications: frequently asked questions

Which GLP-1 medication produces the most weight loss?

Mounjaro (tirzepatide) at 15mg produces the greatest weight loss in trials: around 20% body weight over 72 weeks per SURMOUNT-1. Wegovy (semaglutide 2.4mg) produces around 15% over 68 weeks per STEP-1. Off-label Ozempic at 1.0mg produces less because the dose is capped lower than Wegovy.

Which GLP-1 is cheapest in Australia?

PBS Authority Streamlined Ozempic at $31.60/month (general) for type 2 diabetes patients. For everyone else paying privately, off-label Ozempic is marginally cheapest at the private retail price (varies by pharmacy), followed by Saxenda ($340-$420), Wegovy ($420-$530), and Mounjaro ($450-$580).

Is there a non-injectable GLP-1?

Yes. Rybelsus (oral semaglutide tablets) is TGA-approved for type 2 diabetes in Australia. It is not commonly prescribed for weight loss because the doses available are lower-equivalent than injectable Ozempic/Wegovy. Daily tablet vs weekly injection trade-off.

What is the difference between GIP/GLP-1 dual agonists and single GLP-1 agonists?

Single GLP-1 agonists (Ozempic, Wegovy, Saxenda, Trulicity, Rybelsus) activate only the GLP-1 receptor. Dual GIP/GLP-1 agonists (Mounjaro) activate both. Dual mechanism produces stronger appetite suppression and metabolic effects in trials, leading to different weight-change range in trials.

Are any GLP-1 medications going off-patent soon?

Semaglutide patents in Australia do not expire until around 2031. Tirzepatide patents extend even further. Generic versions are not expected before the early 2030s. Compounded semaglutide is NOT a generic.